celecoxib and gefitinib

celecoxib has been researched along with gefitinib in 31 studies

Research

Studies (31)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (54.84)	29.6817
2010's	14 (45.16)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP	1
Doak, AK; Prusiner, SB; Shoichet, BK; Wille, H	1
Ekins, S; Williams, AJ; Xu, JJ	1
Dalvie, D; Loi, CM; Smith, DA	1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, LW; Chen, Z; Lu, XY; Wang, PF; Wang, ZC; Yan, XQ; Zhang, HW; Zhu, HL	1
Chen, LW; Li, Z; Lu, XY; Lv, PC; Qiu, HY; Wang, PF; Wang, ZC; Yan, XQ; Zhu, HL	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chen, LZ; Kong, FL; Lu, YD; Shen, FQ; Wang, MH; Wang, ZC; Yang, MR; You, LX; Zhu, HL	1
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X	1
Altundag, K; Altundag, O; Boruban, C; Silay, YS	1
Dannenberg, AJ; Gibson, N; Lippman, SM; Subbaramaiah, K	1
Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X	1
Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X	1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H	1
Cho, KH; Cho, MJ; Jun, HJ; Lee, JS; Park, JS; Pyo, H; Zo, JI	1
Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A	1
Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X	1
Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A	1
Chen, L; He, Y; Huang, H; Liao, H; Wei, W	1
Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M	1
Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N	1
Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH	1
Bissonette, R; Brown, PH; Hill, J; Hilsenbeck, SG; Kittrell, F; Medina, D; Zhang, Y	1
Abba, MC; Aldaz, CM; Bissonnette, RP; Brown, PH; Gaddis, S; Hill, J; Hu, Y; Kittrell, FS; Levy, CC; Medina, D	1
Gong, P; Li, H; Li, J; Li, N; Ma, X; Su, F	1
Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG	1
Chu, Q; Dai, H; Duan, Q; Fu, Y; Hu, H; Ji, X; Li, Y; Lin, X; Liu, L; Lu, H; Lu, S; Ma, T; Ni, X; Tian, Q; Wang, F; Xiao, J; Xiu, R; Xu, S; Xue, P; Yuan, P; Zeng, F; Zhang, J; Zhao, X; Zhu, F; Zou, L	1

Reviews

1 review(s) available for celecoxib and gefitinib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

4 trial(s) available for celecoxib and gefitinib

Article	Year
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides	2005
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis	2007
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate	2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular cancer therapeutics, 2008, Volume: 7, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides	2008

Other Studies

26 other study(ies) available for celecoxib and gefitinib

Article	Year
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. European journal of medicinal chemistry, 2010, Volume: 45, Issue:4 Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water	2010
Colloid formation by drugs in simulated intestinal fluid. Journal of medicinal chemistry, 2010, May-27, Volume: 53, Issue:10 Topics: Buffers; Chemical Precipitation; Colloids; Intestine, Small; Light; Microscopy, Electron, Transmission; Pharmaceutical Preparations; Scattering, Radiation; Solubility	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Which metabolites circulate? Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5 Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations	2013
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors. Bioorganic & medicinal chemistry letters, 2015, May-01, Volume: 25, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Pyrazoles; Structure-Activity Relationship; Sulfonamides	2015
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis. Bioorganic & medicinal chemistry letters, 2015, Oct-15, Volume: 25, Issue:20 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Molecular Docking Simulation; Molecular Structure; Pyrazoles; Quantitative Structure-Activity Relationship; Sulfonamides	2015
Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy. Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24 Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Drug Design; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase Inhibitors; Molecular Docking Simulation; Neoplasms; Pyrazoles; Quantitative Structure-Activity Relationship; Thiazoles	2018
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17 Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins	2004
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome	2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides	2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2005
[Molecular-targeted therapy for hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6 Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D	2006
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Aug-15, Volume: 12, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Rabbits; Radiation Tolerance; Sulfonamides	2006
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids	2007
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer, 2007, Dec-15, Volume: 110, Issue:12 Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured	2007
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides	2008
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:3 Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rad51 Recombinase; Sulfonamides	2009
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Incidence; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Suppressor Protein p53	2009
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Protein p53	2009
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines	2015
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. Oncology reports, 2018, Volume: 40, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells. Cell death & disease, 2019, 10-14, Volume: 10, Issue:10 Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mitogen-Activated Protein Kinase Kinases; Pantoprazole; Progression-Free Survival; Proto-Oncogene Proteins c-met; Signal Transduction; Xenograft Model Antitumor Assays	2019